EGFR-TKI治疗S768Ⅰ突变非小细胞肺癌的研究进展

Progress on EGFR-TKI in treatment of non-small cell lung cancer with S768Ⅰ mutation

摘要: 肺癌是死亡率较高的恶性肿瘤之一，近年来非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗进展迅速，尤其是表皮生长因子受体络氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitor，EGFR-TKI）的问世，使得携带EGFR基因敏感突变患者的中位无进展生存期（median progression free survival，mPFS）达到27.7个月，但部分不常见的EGFR突变对TKI的应答效果尚不十分明确。S768Ⅰ突变是EGFR20外显子携带的不常见突变之一，发生率为1%~2%。本文对不同代EGFR-TKI治疗S768Ⅰ单一或复合突变的研究进行综述，旨在为临床决策提供思路。

Abstract: Lung cancer is one of the malignant tumors with high mortality rates. In recent years, considerable progress on the treatment of non-small cell lung cancer has been achieved. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) improves the median progression free survival of patients with sensitive mutations to 27.7 months. However, the therapeutic effect of EGFR-TKI on uncommon mutations remains unknown. S768Ⅰ mutation is an insensitive mutation in the EGFR20 exon, and its incidence rate ranges from 1% to 2%. In this review, the effect of different generation EGFR-TKI on single or complex S768Ⅰ mutation during treatment is discussed.